<>
Children’s Healthcare of Atlanta has launched a phase 1 clinical trial to evaluate a nickel-sized microneedle skin stamp designed to treat peanut allergies. The device, developed by Moonlight Therapeutics Inc., delivers controlled doses of peanut protein directly into the skin to induce desensitization. The trial is currently recruiting adults, with future plans to expand to children as young as 4 years old.
How the Microneedle Stamp Functions
The device uses stainless steel microneedles to administer peanut protein during a brief, three-minute application on the forearm. According to Samir Patel, PhD, president and CEO of Moonlight Therapeutics, the technology provides a minimally invasive delivery method that avoids the need for ingestion.
Unlike traditional skin patches that sit on the surface, this stamp penetrates the outer layer of the skin. Brian Vickery, MD, chief of allergy and immunology at Children’s Healthcare of Atlanta, notes that this method may improve the immune system’s response to allergens. Because the needles are minute, researchers anticipate the application will be less painful than a standard injection.
Did you know?
More than 1.2 million children in the U.S. currently live with a peanut allergy. With the recent discontinuation of an FDA-approved oral powder therapy, the development of new, reliable treatment options has become a priority for clinical researchers.
Clinical Trial Structure and Safety Protocols
The phase 1 trial is funded by a grant from the National Institutes of Health (NIH). The study is designed to prioritize safety and tolerability before moving to broader age groups. The enrollment process follows a tiered approach:
- Initial Cohort: Adults aged 18 to 55.
- Secondary Cohort: Younger teenagers.
- Pediatric Cohort: Children as young as 4 years old.
Participants receive an active stamp on one forearm and a placebo on the other once per week. The procedure occurs under clinical supervision at several institutions, including Emory University, the University of North Carolina at Chapel Hill, the University of Arkansas, the University of Michigan, and a research organization in Nebraska.
Comparing Immunotherapy Approaches
Current food allergy treatments are limited. Historically, patients have relied on subcutaneous injections or oral powders. The microneedle stamp offers a distinct alternative by keeping the treatment localized to the skin.
“The microneedle approach may be a way to safely and precisely deliver a controlled dose of peanut protein to the immune system,” said Vickery, who also serves as the vice-chair of clinical research in the department of pediatrics at Emory University School of Medicine. Researchers plan to start at a one-microgram dose, incrementally increasing the amount to identify the most effective and safe level for long-term immune modulation.
While this technology is designed for potential home use, all current testing is strictly conducted under clinical supervision to ensure patient safety as the study progresses through its initial phases.
Frequently Asked Questions
What is the primary goal of the current phase 1 study?
The study aims to evaluate the safety and tolerability of the microneedle device in human patients, starting with adults, before expanding to younger demographics.
How long does the treatment application take?
The device is designed to be applied to the forearm for approximately three minutes per session.
Is this treatment intended for home use?
While the device is designed for potential home use in the future, it is currently being administered exclusively in a clinical setting as part of the phase 1 trial.
Are you interested in the latest developments in pediatric immunology? Subscribe to our newsletter for updates on clinical trial results and emerging allergy treatments.
Keep reading
